MAPI Research Trust provides reliable, comprehensive and up-to-date information services to research scientists, pharmaceutical companies, and governmental health agencies involved in the fields of Patient-Reported Outcomes (PRO) and Epidemiology worldwide.
Home SERVICES Questionnaire Licensing
RLS-QOL (Johns Hopkins Restless Legs Syndrome)

Developed by:
Richard P. Allen et al. (USA)

Copyright:
Dr Richard Allen holds the copyright to the original Johns Hopkins Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL) and derivative works including a shared copyright on its translations with some of the companies/ Institutions sponsoring the translations.

Reference publication:
Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health. 2005 Mar-Apr;8(2):157-67.


Conditions of use:

1. User Agreement:

User is required to complete and sign a User Agreement in which specific conditions requested by the Author are detailed.

There are two types of user-agreement, one specific to the use of the RLS-QOL in commercial studies, and one specific to the use of the RLS-QOL in clinical practice and not funded academic research.

2. Access Fees:

carre6 Author's royalty fees:

The use of the RLS-QOL in any academic research study is free from any Author’s royalty fees.

The use of the RLS-QOL by “for profit” organizations is subject to author’s royalty fees:
• Less than 100 administrations/reproductions =  105 €* per study, plus 105 €* per translated version (excluding US English original version)
• 101 to 1,000 administrations/reproductions = 1,050 €* per study, plus 210 €* per translated version (excluding US English original version)
• Greater than 1,001 administrations/reproductions = 2,100 €* per study, plus 210 €* per translated version (excluding US English original version)

carre6 Distribution fees are requested according to the study design and context of use of the questionnaire:

1. In not-funded academic research (1) and individual clinical practice: free of charge

2. In funded academic research (2): 300 €* per study + an additional 50 €* per language version requested.

3. In commercial studies (3) involving "for-profit" organizations: 600 €* per study + an additional 250 €* per language version requested.

* excluding VAT

(1) Not funded academic research: if the project is not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds then fees are waived.

(2) Funded academic research: projects receiving funding from commerce, government, EU should anticipate paying the corresponding fees.

(3) Commercial studies (industry, CRO, any for-profit companies).


Review copy:

Original US English version available for review purpose only. Please click here to access.


Contact information:

MAPI Research Trust

27 rue de la Villette
F - 69003 LYON
Tel: +33 4 72 13 65 75
Fax: +33 4 72 13 55 73
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Please have the appropriate User Agreement -- i.e. "Commercial studies" or "Academic research/Clinical practice" -- completed, dated and signed and return one original copy to MAPI Research Trust by post. As soon as we receive it, we will process your request.

More information on the RLS-QOL on PROQOLID

[ BACK ]
 

To access our catalog, please click here.

New questionnaires distributed by MAPI Research Trust

ACCEPT (Chronic Treatment Acceptance Questionnaire)
MAPI SAS / Registrat MAPI (France)

ADRQL (Alzheimer Disease Related Quality of Life)
Black Betty S, Kasper Judith D and Rabins Peter V. - Johns Hopkins Medical INstitutions (USA)

Barthel Index questionnaire
The Maryland State Medical Society - MedChi (USA)

ESS (Epworth Sleepiness Scale) 
Murray W. Johns (Australia)

FIRST (Fibromyalgia Rapid Screening Tool)
Serge Perrot & Didier Bouhassira (France)

PDSS-2 (Parkinson's Disease Sleep Scale)
Ray Chaudhuri (UK) & Claudia Trenkwalder (Germany)

Skindex questionnaire 
Mary-Margaret Chren (USA)

TRIM-D and TRIM-D Device (Treatment Related Impact Measure for Diabetes)
Novo Nordisk (Denmark)